3,4-Dihydro-1H-[1,3]oxazino[4,5-c]acridines as a new family of cytotoxic drugs
Authors:
- 1 September 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (17) , 4641-4643
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapyBioorganic & Medicinal Chemistry Letters, 2006
- 4-Hydroxymethyl-3-aminoacridine Derivatives as a New Family of Anticancer AgentsJournal of Medicinal Chemistry, 2003
- Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancerEuropean Journal of Cancer, 2003
- Interest of Acridine Derivatives in the Anticancer ChemotherapyCurrent Pharmaceutical Design, 2001
- Substituent Influences on the Stability of the Ring and Chain Tautomers in 1,3-O,N-Heterocyclic Systems: Characterization by13C NMR Chemical Shifts, PM3 Charge Densities, and Isodesmic ReactionsThe Journal of Organic Chemistry, 2001
- Current status of pyrazoloacridine as an anticancer agentInvestigational New Drugs, 1999
- Dual topoisomerase I/II poisons as anticancer drugsExpert Opinion on Investigational Drugs, 1997
- Antibody-directed enzyme prodrug therapy (ADEPT): a reviewAdvanced Drug Delivery Reviews, 1997
- Structure−Activity Relationship for Antineoplastic Imidazoacridinones: Synthesis and Antileukemic Activity in VivoJournal of Medicinal Chemistry, 1996
- Ring-chain tautomerism in 1,3-oxazinesThe Journal of Organic Chemistry, 1987